Objective: To evaluate the potential anti-hepatitis C virus (HCV) activities of Cladogynos orientalis Zipp. ex Span and to investigate the molecular mode of action. Methods: Ethanolic and water extracts from various p...Objective: To evaluate the potential anti-hepatitis C virus (HCV) activities of Cladogynos orientalis Zipp. ex Span and to investigate the molecular mode of action. Methods: Ethanolic and water extracts from various parts of Cladogynos orientalis were examined for cytotoxicity by MTT assay. Sub-cytotoxic concentrations of the extracts were used for further determining anti-HCV activity using cell culture-derived HCV genotype 2a propagated in HepaRG cell line. Immunofluorescence assay was performed to observe the effect on viruses at the pre-entry step. Mode of action at the post-entry step was investigated for the viral RNA and protein expressions by real time RT-PCR and Western blotting assays, respectively. Results: Although Cladogynos orientalis water extracts exhibited lower cytotoxicity than ethanolic extracts, all ethanolic extracts from roots, stems, and leaves of Cladogynos orientalis exhibited higher anti-HCV activities than water extracts. The highest anti-HCV activity was observed in infected cells treated with the extracts 5 h after absorption. No extracts showed pre-viral entry effect. At the post-viral entry step, only leaf ethanolic extracts inhibited NS5B expression, while all extracts did not inhibit HCV NS3 expression. Conclusions: Cladogynos orientalis ethanolic extracts could be further studied and the major active compound needs to be identified as a promising source for anti-HCV agents.展开更多
Objective To analyze the association between mutation（s） in preS region of HBV and hepatitis B disease progress in Chinese patients with genotype C chronic HBV infection. Methods Ninety-three patients with chronic g...Objective To analyze the association between mutation（s） in preS region of HBV and hepatitis B disease progress in Chinese patients with genotype C chronic HBV infection. Methods Ninety-three patients with chronic genotype C HBV infection, including 24 asymptomatic carriers （ASC）, 26 patients with chronic hepatitis B （CHB）, 22 patients with liver cirrhosis （LC） and 21 HCC patients were investigated. Levels of HBV DNA, HBeAg, alanine aminotransferase （ALT）, asparate transaminase （AST） were measured. HBV preS region was analyzed by PCR direct sequencing. Results The prevalence of preS T3098C and T53C mutations ofgenotype C HBV was significantly higher in LC and HCC patients than ASC and CHB patients. The rate ofT3098C mutation in ASC, CHB, LC, and HCC patients were 0.00% （0/24）, 3.85% （1/26）, 9.09% （2/22）, and 30.77% （8/22）, respectively （P=0.0015）, while the rate of T53C mutation was I2.50% （3/24）, 3.85% （1/26）, 40.91% （9/22）, and 42.31% （11/26）, respectively （P=0.0012）. Conclusion The frequency of genotype C HBV preS T3098C and T53C mutations is associated with hepatitis B infection progression.展开更多
Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin....Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti- HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy.展开更多
目的了解无偿献血人群丙型肝炎病毒(HCV)感染者中隐匿性乙肝感染(OBI)率,为进一步阐明HCV/OBI的作用机制提供科学依据。方法采用盖立复PROCLEIX TIGRIS、罗氏cobas s 201和罗氏E601等仪器对2011年1月—2015年7月广州无偿献血者中的933(...目的了解无偿献血人群丙型肝炎病毒(HCV)感染者中隐匿性乙肝感染(OBI)率,为进一步阐明HCV/OBI的作用机制提供科学依据。方法采用盖立复PROCLEIX TIGRIS、罗氏cobas s 201和罗氏E601等仪器对2011年1月—2015年7月广州无偿献血者中的933(人)份HCV感染者标本做HBV DNA和抗-HBc检测,比较HCV单纯感染者和HCV/OBI共感染者之间性别、年龄、民族和转氨酶的差异;巢式PCR扩增HCV/OBI共感染者HCV C区和S区,并构建进化树和基因分型,荧光定量PCR检测HCV和HBV的病毒载量;另外,随机选取同期本地HCV 6a基因型的44名单纯HCV感染者和16名HCV/HBV共感染者最为对照组,通过巢式PCR扩增各组HCV C区,并对3组对象的HCV核心蛋白氨基酸序列做比对分析。结果本组HCV感染的献血者标本中,有6(人)份HBV DNA和抗-HBc阳性,亦即OBI感染率为6.43‰(6/933);该6份HCV/OBI共感染标本的HCV基因型中6a占83.3%(5/6)、1b占16.7%(1/6),HCV病毒载量(log_(10)IU/mL)为3.8—5.7(5.0±0.69)。HCV单纯感染者和HCV/OBI共感染者的性别、年龄、民族、籍贯和ALT均无明显差异(P>0.05)。HCV单纯感染者、HCV/HBV共感染者和HCV/OBI共感染者HCV核心蛋白序列氨基酸变异数分别为0.8±1.3 vs 0.7±1.5 vs 0.4±0.5(P>0.05),没有在HCV/OBI共感染者中发现一致性的结构或突变规律。结论广州地区无偿献血人群HCV感染者中的OBI阳性率较高。展开更多
目的将深度测序法用于HCV感染者中不同基因型/亚型混合感染的检测。方法 2例HCV RNA阳性血浆标本(标记为1和2号标本),以NS5B和E1编码区为目的基因,经RT-PCR扩增后做sanger核苷酸序列测定,对其做基因分型发现2个编码区的分型结果后,重复3...目的将深度测序法用于HCV感染者中不同基因型/亚型混合感染的检测。方法 2例HCV RNA阳性血浆标本(标记为1和2号标本),以NS5B和E1编码区为目的基因,经RT-PCR扩增后做sanger核苷酸序列测定,对其做基因分型发现2个编码区的分型结果后,重复3次NS5B基因PCR扩增;合并3次PCR产物用Ion TorrentTM半导体测序仪做深度测序。获得的序列用Geneious软件的"The map to reference algorithm"和"De novo assembly"2种方法做序列分析和比对,并用Mega 5构建进化树。结果 sanger测序:1、2号标本NS5B基因分型均为1b,E1基因分型均为2a;深度测序:2个标本均为HCV 1b与2a混合感染,其中The map to reference algorithm(Geneious)方法显示,1号标本中1b占92.7%、2a占3.8%、没有比对到的序列(unused seq)占3.5%,2号标本相应为84.3%、5.4%,没有比对到的序列占10.3%;De novo assembly(Geneious)方法显示,1号标本中1b占96.3%、2a占3.7%,2号标本相应为94.1%、5.9%。结论深度测序技术可以精确地获得HCV混合感染的不同基因型/亚型信息,De novo assembly(Geneious)分析HCV的深度测序数据更为精确和直观。展开更多
基金supported by National Research Council of Thailand and Faculty of Pharmacy, Mahidol University
文摘Objective: To evaluate the potential anti-hepatitis C virus (HCV) activities of Cladogynos orientalis Zipp. ex Span and to investigate the molecular mode of action. Methods: Ethanolic and water extracts from various parts of Cladogynos orientalis were examined for cytotoxicity by MTT assay. Sub-cytotoxic concentrations of the extracts were used for further determining anti-HCV activity using cell culture-derived HCV genotype 2a propagated in HepaRG cell line. Immunofluorescence assay was performed to observe the effect on viruses at the pre-entry step. Mode of action at the post-entry step was investigated for the viral RNA and protein expressions by real time RT-PCR and Western blotting assays, respectively. Results: Although Cladogynos orientalis water extracts exhibited lower cytotoxicity than ethanolic extracts, all ethanolic extracts from roots, stems, and leaves of Cladogynos orientalis exhibited higher anti-HCV activities than water extracts. The highest anti-HCV activity was observed in infected cells treated with the extracts 5 h after absorption. No extracts showed pre-viral entry effect. At the post-viral entry step, only leaf ethanolic extracts inhibited NS5B expression, while all extracts did not inhibit HCV NS3 expression. Conclusions: Cladogynos orientalis ethanolic extracts could be further studied and the major active compound needs to be identified as a promising source for anti-HCV agents.
基金supported by the financial grants from Beijing Municipal Science & Technology Commission (D08050702870000)Basic Research Project ("973"Project:2005CB523104)+3 种基金the National Projects on the Control of Major Infectious Diseases (Grant no.2008ZX10002-012)supported by the financial grants from Beijing Municipal Science & Technology Commission (D0805700650805)the National Projects on Major Infectious Diseases, Ministry of Science and Technology of China (No.2008ZX10002-12No.2008ZX10002-004)
文摘Objective To analyze the association between mutation（s） in preS region of HBV and hepatitis B disease progress in Chinese patients with genotype C chronic HBV infection. Methods Ninety-three patients with chronic genotype C HBV infection, including 24 asymptomatic carriers （ASC）, 26 patients with chronic hepatitis B （CHB）, 22 patients with liver cirrhosis （LC） and 21 HCC patients were investigated. Levels of HBV DNA, HBeAg, alanine aminotransferase （ALT）, asparate transaminase （AST） were measured. HBV preS region was analyzed by PCR direct sequencing. Results The prevalence of preS T3098C and T53C mutations ofgenotype C HBV was significantly higher in LC and HCC patients than ASC and CHB patients. The rate ofT3098C mutation in ASC, CHB, LC, and HCC patients were 0.00% （0/24）, 3.85% （1/26）, 9.09% （2/22）, and 30.77% （8/22）, respectively （P=0.0015）, while the rate of T53C mutation was I2.50% （3/24）, 3.85% （1/26）, 40.91% （9/22）, and 42.31% （11/26）, respectively （P=0.0012）. Conclusion The frequency of genotype C HBV preS T3098C and T53C mutations is associated with hepatitis B infection progression.
文摘Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti- HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy.
文摘目的了解无偿献血人群丙型肝炎病毒(HCV)感染者中隐匿性乙肝感染(OBI)率,为进一步阐明HCV/OBI的作用机制提供科学依据。方法采用盖立复PROCLEIX TIGRIS、罗氏cobas s 201和罗氏E601等仪器对2011年1月—2015年7月广州无偿献血者中的933(人)份HCV感染者标本做HBV DNA和抗-HBc检测,比较HCV单纯感染者和HCV/OBI共感染者之间性别、年龄、民族和转氨酶的差异;巢式PCR扩增HCV/OBI共感染者HCV C区和S区,并构建进化树和基因分型,荧光定量PCR检测HCV和HBV的病毒载量;另外,随机选取同期本地HCV 6a基因型的44名单纯HCV感染者和16名HCV/HBV共感染者最为对照组,通过巢式PCR扩增各组HCV C区,并对3组对象的HCV核心蛋白氨基酸序列做比对分析。结果本组HCV感染的献血者标本中,有6(人)份HBV DNA和抗-HBc阳性,亦即OBI感染率为6.43‰(6/933);该6份HCV/OBI共感染标本的HCV基因型中6a占83.3%(5/6)、1b占16.7%(1/6),HCV病毒载量(log_(10)IU/mL)为3.8—5.7(5.0±0.69)。HCV单纯感染者和HCV/OBI共感染者的性别、年龄、民族、籍贯和ALT均无明显差异(P>0.05)。HCV单纯感染者、HCV/HBV共感染者和HCV/OBI共感染者HCV核心蛋白序列氨基酸变异数分别为0.8±1.3 vs 0.7±1.5 vs 0.4±0.5(P>0.05),没有在HCV/OBI共感染者中发现一致性的结构或突变规律。结论广州地区无偿献血人群HCV感染者中的OBI阳性率较高。
文摘目的将深度测序法用于HCV感染者中不同基因型/亚型混合感染的检测。方法 2例HCV RNA阳性血浆标本(标记为1和2号标本),以NS5B和E1编码区为目的基因,经RT-PCR扩增后做sanger核苷酸序列测定,对其做基因分型发现2个编码区的分型结果后,重复3次NS5B基因PCR扩增;合并3次PCR产物用Ion TorrentTM半导体测序仪做深度测序。获得的序列用Geneious软件的"The map to reference algorithm"和"De novo assembly"2种方法做序列分析和比对,并用Mega 5构建进化树。结果 sanger测序:1、2号标本NS5B基因分型均为1b,E1基因分型均为2a;深度测序:2个标本均为HCV 1b与2a混合感染,其中The map to reference algorithm(Geneious)方法显示,1号标本中1b占92.7%、2a占3.8%、没有比对到的序列(unused seq)占3.5%,2号标本相应为84.3%、5.4%,没有比对到的序列占10.3%;De novo assembly(Geneious)方法显示,1号标本中1b占96.3%、2a占3.7%,2号标本相应为94.1%、5.9%。结论深度测序技术可以精确地获得HCV混合感染的不同基因型/亚型信息,De novo assembly(Geneious)分析HCV的深度测序数据更为精确和直观。
